Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS627 vs. Perjeta PK Study in Healthy Males
NCT04820439Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hs627 in breast cancer and gastric cancer (GC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Area under the plasma concentration versus time curve from zero to infinity at 150 days. Started Oct 2020; status: completed.
02
Drugs
hs627
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT04820439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820439.